Reshape Lifesciences INC

Vyome Holdings reports Q1 2026 financial results, highlighting a strengthened cash position and progress on its lead clinical asset, VT-1953.

Vyome Holdings, Inc. announced a significant reduction in its authorized common stock from 300 million to 50 million shares, alongside the election of new directors and ratification of auditors.

Livechain, a Vyome subsidiary, completed an all-stock acquisition of Humanyze's senior secured debt, positioning itself in the AI HR market and paving the way for a potential national exchange uplisting in 2026.

An independent analysis projects Vyome Holdings' lead clinical candidate, VT-1953, for malignant fungating wounds, to reach a U.S. asset value of $1 billion after successful Phase 3 completion, with peak annual sales of $696 million.

Vyome Holdings' subsidiary, LiveChain, Inc., entered a binding letter of intent to acquire a senior secured convertible note from Remus Capital, issued by Humanyze, in exchange for LICH common stock.

Vyome Holdings announced its third fiscal quarter 2025 financial results and significant corporate and clinical milestones, including positive interim Phase 2 data for VT-1953 and an AI strategy launch.

Vyome Holdings, Inc. filed its Q1 2026 10-Q, detailing a significant increase in R&D expenses and a new exclusive license agreement for JAK inhibitor assets.

Vyome Holdings, Inc. reported a significant net loss increase in Q3 2025 following its merger with Reshape Lifesciences and a strategic shift towards biotechnology, despite raising substantial capital.

ReShape Lifesciences reported a significant revenue contraction and increased net losses, raising substantial doubt about its ability to continue as a going concern, despite recent capital raises.

Reshape Lifesciences reports a net income of $1.474 million for Q1 2025, while navigating a pending merger with Vyome Therapeutics and an asset sale to Ninjour Health International.

ReShape Lifesciences reports a net loss for Q3 2024, while navigating a strategic shift towards a digital model and planning a merger with Vyome Therapeutics.

ReShape Lifesciences reports a decrease in revenue for Q2 2024, alongside a strategic shift towards a digital model and a planned merger with Vyome Therapeutics.

Vyome Holdings, Inc. reported a significant net loss for fiscal year 2025, while advancing its lead drug candidate VT-1953 for malignant fungating wounds and outlining plans for future clinical trials and capital raises.

ReShape Lifesciences Inc. details its 2024 financial performance and strategic initiatives, including a pending merger with Vyome Therapeutics and an asset sale to Ninjour Health International, while navigating challenges in the weight-loss market.

ReShape Lifesciences Inc. focuses on strategic growth pillars, including cost reduction and product portfolio expansion, while facing revenue declines due to market competition.

Vyome Holdings, Inc. director Stanley D. Pomichter III was granted 17,833 stock options at an exercise price of $0.66 following the merger with Vyome Therapeutics.

Mohanjit Jolly, a director of Vyome Holdings, Inc., reported the indirect acquisition of 454,456 shares of common stock following the merger of Vyome Therapeutics, Inc. into a subsidiary of the Issuer.

Vyome Holdings Director John Tincoff III was granted 17,833 stock options following the merger with Vyome Therapeutics, Inc.

Vyome Holdings, Inc. director Shiladitya Sengupta was granted 624,432 fully vested stock options following the merger with Vyome Therapeutics.

Vyome Holdings, Inc. President and CEO, Nelabhotla Venkateswarlu, was granted 615,149 fully vested stock options following the merger with Vyome Therapeutics.

Vyome Holdings' President and CEO, Nelabhotla Venkateswarlu, acquired 7 shares of common stock following the merger with Vyome Therapeutics.

Vyome Holdings, Inc. announces its 2026 Annual Meeting of Stockholders to vote on director elections, a significant reduction in authorized common stock, auditor ratification, and executive compensation.

Vyome Holdings, Inc. announced its 2025 Annual Meeting of Stockholders to vote on director elections, a new equity incentive plan, auditor ratification, and executive compensation.

ReShape Lifesciences is holding a special meeting to seek stockholder approval for a reverse stock split, warrant exercises, and an equity line of credit issuance to meet Nasdaq listing requirements and fund operations.

ReShape Lifesciences has filed a registration statement to register an additional $9,152,802 in securities, including common stock and warrants.

ReShape Lifesciences is launching a best-efforts offering of up to 1,779,360 units, each containing a share of common stock or a pre-funded warrant and a warrant, aiming to raise capital for general corporate purposes including merger expenses.

ReShape Lifesciences is seeking to raise capital through a unit offering to fund operations while it awaits the closing of its merger with Vyome Therapeutics and the sale of its assets to Ninjour Health International.

ReShape Lifesciences details the terms of common stock purchase warrants and a merger agreement with Vyome Therapeutics, outlining exercise conditions, price adjustments, and potential alternative considerations.

ReShape Lifesciences files an amendment to its registration statement for the resale of common stock by Ascent Partners Fund LLC, as the company navigates a proposed merger with Vyome Therapeutics and asset sale to Ninjour Health International Limited.

ReShape Lifesciences is undertaking a best-efforts unit offering to raise capital while navigating a pending merger and asset sale.

A group of investors led by Dominion Capital LLC has filed an amended Schedule 13D, disclosing a reduction in their beneficial ownership of ReShape Lifesciences Inc. common stock to 0.76%, triggering an exit filing.

A group of investors led by Dominion Capital LLC and Ascent Partners Fund LLC has increased its beneficial ownership in ReShape Lifesciences Inc. to 9.9%, signaling support for the company's strategic merger and providing potential future capital.

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G, disclosing beneficial ownership of 0.33% of ReShape Lifesciences Inc.'s common stock.

CVI Investments and Heights Capital Management report 0% beneficial ownership in ReShape Lifesciences Inc., indicating a full divestment.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri reported a combined beneficial ownership of 0.003% in ReShape Lifesciences Inc. common stock.

L1 Capital Global Opportunities Master Fund, Ltd. has reported a 9.85% beneficial ownership stake in ReShape Lifesciences Inc., as detailed in a recent Schedule 13G filing with the SEC.

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have jointly disclosed beneficial ownership of 5.71% of ReShape Lifesciences Inc.'s common stock, primarily through warrants.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a beneficial ownership of 5.7% in ReShape Lifesciences Inc., primarily through warrants.